Abstract
Outcomes in Patients (pts) with R/R Large B-Cell Lymphoma (LBCL) Who Received Nonconforming Product (NCP) to Commercial Release of Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have